Hepatitis C Virus and the Humoral Immune System
2 other identifiers
observational
161
1 country
1
Brief Summary
The purpose of this study is to measure specific chemokines, antibodies, and antibody-producing B cells in the blood of patients with hepatitis C virus (HCV) infection. Our hypothesis is that changes in chemokine levels affect the development of an effective immune response against HCV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2001
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2001
CompletedFirst Submitted
Initial submission to the registry
September 19, 2005
CompletedFirst Posted
Study publicly available on registry
September 22, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedAugust 9, 2013
August 1, 2013
11.7 years
September 19, 2005
August 6, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Define the relationships between HCV infection, B cell phenotype, and B cell function
Define the relationships between HCV infection, B cell phenotype, and B cell function
5 years
Study Arms (5)
HCV infection
current HCV infection, including intravenous drug users
cryoglobulinemia
cryoglobulinemia and without HCV infection
chronic liver disease
chronic liver disease not due to hepatitis C virus infection
Sustained Virologic responders
successfully treated for HCV infection
normal
normal, healthy volunteers
Eligibility Criteria
primary care clinics of doctors at NYPH and the NYC metropolitan area
You may qualify if:
- Healthy volunteers, no liver disease
- Chronic infection with hepatitis C virus
- Other chronic liver disease unrelated to hepatitis C virus
- Subjects in all groups must have sufficiently healthy veins to allow blood collection.
You may not qualify if:
- Any medical condition that, in the opinion of the investigators, precludes the patient's participation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Rockefeller University Hosital
New York, New York, 10021, United States
Related Publications (1)
Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, Jacobson IM, Rice CM, Dustin LB. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008 Feb 1;111(3):1344-56. doi: 10.1182/blood-2007-07-101717. Epub 2007 Oct 17.
PMID: 17942751DERIVED
Related Links
Biospecimen
whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lynn B Dustin, PHD
Rockefeller University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 19, 2005
First Posted
September 22, 2005
Study Start
September 1, 2001
Primary Completion
May 1, 2013
Study Completion
May 1, 2013
Last Updated
August 9, 2013
Record last verified: 2013-08